Aerovate Therapeutics Inc... (AVTE)
NASDAQ: AVTE
· Real-Time Price · USD
2.68
0.00 (0.00%)
At close: Apr 28, 2025, 3:59 PM
Aerovate Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -48.96M | -69.63M | -84.61M | -87.94M | -82.19M | -75.52M | -70.13M | -64.16M | -57.12M | -51.51M | -44.71M | -37.31M | -31.09M | -22.96M | -18.41M | -14.53M | -10.96M |
Depreciation & Amortization | -1.88M | -1.63M | -1.61M | 109K | 103K | 96K | 88K | 83K | 78K | 68K | 56K | 39K | 24K | 15K | 8K | 5K | 3K |
Stock-Based Compensation | 8.3M | 11.31M | 13.32M | 14.55M | 13.72M | 11.91M | 10.38M | 8.65M | 6.84M | 5.48M | 4.6M | 3.95M | 3.04M | 2.04M | 1.21M | 389K | 74K |
Other Working Capital | 175K | -4.62M | 5.8M | 3.23M | 3.93M | 9.96M | 6.39M | 3.27M | 5.03M | 6.39M | 941K | -1.74M | -2.74M | -7.12M | -1.67M | 503K | -924K |
Other Non-Cash Items | -5.21M | -1.72M | 2.45M | 4.57M | 4.63M | 1.29M | -2.7M | -2.19M | -1.61M | -910K | -308K | -256K | 332K | -435K | -444K | -140K | -90K |
Deferred Income Tax | n/a | n/a | -4.35M | -4.35M | -4.35M | -4.35M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -2.15M | -6.1M | 3.27M | 1.96M | 2.48M | 9.8M | 5.52M | 6.66M | 6.93M | 7.75M | 3.01M | -818K | -1.31M | -6.51M | -5K | 974K | -213K |
Operating Cash Flow | -49.9M | -71.2M | -74.95M | -74.52M | -69.03M | -56.78M | -56.84M | -50.95M | -44.88M | -39.12M | -37.35M | -34.16M | -29.29M | -27.4M | -17.19M | -13.1M | -10.45M |
Capital Expenditures | n/a | n/a | -64K | -96K | -126K | -142K | -82K | -83K | -183K | -195K | -276K | -299K | -169K | -181K | -96K | -40K | -40K |
Cash Acquisitions | n/a | n/a | -5.71K | 7.39K | 3.37K | -12.02K | -20.8K | -38.57K | -42.88K | -27.49K | -13K | -8.32K | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -4.93M | -19.68M | -47.47M | -90.39M | -123.12M | -123.98M | -146.45M | -124.18M | -130.34M | -147.62M | -210.62M | -185.04M | -146.14M | -113.25M | n/a | n/a | n/a |
Sales Maturities Of Investments | 51.85M | 62.58M | 96.08M | 109.83M | 128.58M | 136M | 167.25M | 162.75M | 173.22M | 154.74M | 89.99M | 59.74M | 12.52M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 13.13M | 21.96M | 8.84M | 8.83M | 8.83M | 12.02K | 20.8K | 38.57K | 42.88K | -20.34M | -133.61M | -133.62M | -133.62M | -113.25M | n/a | n/a | n/a |
Investing Cash Flow | 60.05M | 56.03M | 48.55M | 19.35M | 5.33M | 11.88M | 20.71M | 38.49M | 42.7M | 6.93M | -120.9M | -125.6M | -133.79M | -113.43M | -96K | -40K | -40K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 24.65M | 25.12M | 25.34M | 25.33M | 46.24M | 46M | 45.89M | 45.91M | 619K | 396K | 39K | 128.31M | 127.3M | 127.19M | 127.19M | 1.39M | 2.4M |
Financial Cash Flow | 24.96M | 25.43M | 25.34M | 25.33M | 46.24M | 46M | 45.89M | 45.91M | 619K | 396K | -211K | 128.06M | 182.57M | 190.46M | 190.71M | 71.31M | 16.8M |
Net Cash Flow | 35.1M | 10.26M | -1.06M | -29.83M | -17.45M | 1.09M | 9.76M | 33.44M | -1.57M | -31.8M | -158.46M | -31.69M | 19.5M | 49.62M | 173.42M | 58.18M | 6.31M |
Free Cash Flow | -49.9M | -71.2M | -75.01M | -74.61M | -69.15M | -56.92M | -56.92M | -51.03M | -45.07M | -39.32M | -37.63M | -34.45M | -29.45M | -27.58M | -17.29M | -13.14M | -10.49M |